Pituitary tumors are generally benign, although in rare cases aggressive pituitary tumors
(APTs) and carcinomas present important diagnostic and therapeutic challenges and are …

Objective To collect outcome data in a large cohort of patients with aggressive pituitary
tumours (APT)/carcinomas (PC) and specifically report effects of temozolomide (TMZ) …

Context Despite growing evidence that temozolomide (TMZ) therapy is effective for the
treatment of aggressive pituitary tumors (APTs) or carcinomas (PCs), individual therapy …

Pituitary adenomas are common intracranial tumors that are mainly considered as benign.
Rarely, these tumors can exhibit an aggressive behavior, characterized by gross invasion of …

Temozolomide (TMZ) has recently been recommended as a novel approach in the
management of aggressive pituitary tumors. Herein, we present the case of a 43-year-old …

Objectives Only few retrospective studies have reported an efficacy rate of temozolomide
(TMZ) in pituitary tumors (PT), all around 50%. However, the long-term survival of treated …

Eur J Clin Invest 2011; 41 (10): 1133–1148 Abstract Background Aggressive pituitary
tumours are associated with substantial morbidity and mortality. Treatment options are often …

Once temozolomide has failed, no other treatment is recommended for pituitary carcinomas
and aggressive pituitary tumors. Recently, the use of immune checkpoint inhibitors (ICIs) has …

Background Treatment of aggressive pituitary adenomas typically involves a multimodality
approach based on histopathological features and may include pharmacotherapy, surgery …

Background Pituitary tumours are common and easily treated by surgery or medical
treatment in most cases. However, a small subset of pituitary tumours does not respond to …